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Sodium tungstate is a novel agent in the treatment of obesity. In diet-induced obese rats, it is able
to reduce body weight gain by increasing energy expenditure. This study evaluated the role of
leptin, a key regulator of energy homeostasis, in the tungstate antiobesity effect. Leptin receptor-
deficient Zucker fa/fa rats and leptin-deficient ob/ob mice were treated with tungstate. In lean
animals, tungstateadministration reducedbodyweightgainandfood intakeand increasedenergy
expenditure. However, in animals with deficiencies in the leptin system, treatment did notmodify
these parameters. In ob/ob mice in which leptin deficiency was restored through adipose tissue
transplantation, treatment restored the tungstate-induced body weight gain and food intake
reduction as well as energy expenditure increase. Furthermore, in animals in which tungstate
administration increased energy expenditure, changes in the expression of key genes involved in
brown adipose tissue thermogenesis were detected. Finally, the gene expression of the hypotha-
lamic neuropeptides,Npy,Agrp, andCart, involved in the leptin regulationof energy homeostasis,
wasalsomodifiedby tungstate ina leptin-dependentmanner. In summary, the results indicate that
the effectiveness of tungstate in reducing body weight gain is completely dependent on a func-
tional leptin system. (Endocrinology 150: 642–650, 2009)
Obesity is caused by a prolonged energy homeostasis imbal-ance as a consequence of a greater energy intake than en-
ergy expenditure (1).This imbalance causes a complexmetabolic
disorder characterized by an excessive accumulation of body fat
and associated comorbidities, such as diabetes, hypertension,
cardiovascular disease, and cancer.Theprevalenceof obesityhas
increased during the last decades, reaching pandemic propor-
tions. Currently available antiobesity drugs have limited effects
on body weight loss and display several adverse effects (2). Con-
sequently, the development of more effective and safer drugs is
becoming imperative.
As we previously reported, oral administration of sodium
tungstate decreases body weight gain and adiposity in diet-in-
duced obese rats, without modifying food intake, intestinal fat
absorption, or growth rate (3). Tungstate also ameliorates dys-
lipemia and insulin resistance in these animals and reduces body
weight gain in lean control rats (4). These effects aremediated by
an increase in whole-body energy dissipation and, in adipose
tissue, by changes in the expression of genes and proteins in-
volved in fatty acid oxidation and mitochondrial uncoupling (4,
5). Compared with other inorganic compounds with similar in-
sulin-like properties, tungstate has a rather low toxicity in rats
(6). Short- or long-term administration of tungstate in rodents
has neither hepatotoxic nor nephrotoxic effects, as several stud-
ies have shown (4, 6, 7). Taken together, these data support the
use of tungstate as a safe and effective antiobesity drug.
Leptin is a key adipokine in the regulation of energy ho-
meostasis (8, 9). In both rodents andhumans, defects in the genes
encoding either leptin (9, 10) or its receptor (11–13) lead to
severe obesity. Leptin is produced mainly by adipose tissue and
is released into the circulatory system in correlation with fat
content. Leptin binds to its receptors located in the brain and
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produces a decrease in food intake and an increase in energy
expenditure (14). Specifically, leptin acts on the arcuate nucleus
of the hypothalamus, a key target area of the brain, in which it
simultaneously inhibits orexigenic neuropeptide Y (NPY)/ag-
outi-related peptide (AGRP) expressing neurons (15, 16) and
activates anorexigenic proopiomelanocortin (POMC)/cocaine-
and amphetamine-related transcript (CART) expressing neu-
rons (17, 18). The strong involvement of leptin in body weight
and energy expenditure regulation led us to examinewhether the
effects of tungstate on the regulation of body weight are leptin
dependent. The purpose of the study was to improve our under-
standing of the mechanisms of tungstate antiobesity effects and
unravel the role of the leptin system.
Materials and Methods
Animals and treatment
Twelve-week-old male lean (/?) and obese leptin receptor-deficient
(fa/fa) Zucker rats or male lean (/?) and obese leptin-deficient (ob/ob)
mice (Charles River Laboratories, Sta. Perpetua deMogoda, Spain)were
caged individually in a 12-h light, 12-h dark cycle in a temperature- and
humidity-controlled environment. Animals were fed ad libitum with
standard chow diet (type A04; Panlab, Barcelona, Spain).
Treatment was orally administered through a solution of 2 mg/ml
sodium tungstate (Na2WO4 2H2O; Carlo Erba, Milano, Italy) in dis-
tilled drinking water for 30 d ad libitum. Using this concentration, the
tungstate dose ingested daily was 225 mg/kg body weight for rats and
180 mg/kg body weight for mice. Throughout the experimental period,
water, food and body weight of all animals were recorded periodically.
At the end of the treatment period, animals were killed with inhaled
isofluorane overdose, with the exception of mice used for hypothalamus
isolation,whichwere decapitated. In decapitatedmice, brainwas rapidly
removed from the skull and hypothalamus was immediately dissected
using consistent landmarks, being bordered by the optic chiasma, mam-
millary bodies, and hypothalamic sulcus. Then was placed in an Eppen-
dorf tube, weighed, and frozen. Interscapular brown adipose tissue
(BAT) was excised and rapidly frozen in liquid nitrogen. All procedures
were conducted in accordance with the guidelines of laboratory animal
care (European Union regulations; O. J. of the European Communities
L358/1, and local government guidelines) and approved by the Animal
Research Committee of the University of Barcelona.
Adipose tissue transplantation
Adipose tissue transplantation was performed in 12-wk-old ob/ob
male mice as previously described (19) with several modifications. Four
explants of 100–150mg of epididymal adipose tissue (eWAT) from lean
mice were transplanted sc in four incisions divided between the scapular
and lumbar zones. Transplanted animals were divided into two groups:
untreated (ob/ob txUT) and tungstate-treated (ob/ob txT) mice. An ad-
ditional group of ob/obmice transplantedwith ob/ob eWATwas used as
a leptin deficiency transplant control (ob/ob txCN). The experimentwas
performed over 4 wk. After this period, the transplanted fat depots were
surgically excised in some of the ob/ob txTmice; in these animals tung-
state treatment was either maintained for an additional 14 d or
withdrawn.
Recombinant-leptin treatment
Recombinant murine leptin (Sigma-Aldrich, St. Louis, MO) was dis-
solved following the manufacturer’s instructions. Either vehicle (NaCl,
154mmol/liter) or leptin (0.5g/g bodyweight) was administered twice
daily to 12-wk-oldmale ob/obmice by ip injection at 0800 h and 1900 h
for 5 d. Half of the leptin-treated mice were simultaneously cotreated
orally with tungstate, as described above.
Metabolic measurements
All animals were fasted for 6 h before metabolic measurements.
Blood samples were collected from the tail vein using a capillary blood
collection system with EDTA (Sarstedt, Nu¨mbrecht, Germany). Plasma
triglycerides (TGs) and nonesterified fatty acids (NEFA) levels, were
measured using colorimetric kits TG PAP-150 (BioMe´rieux, Marcy
l’Etoile, France) and NEFA C (Wako, Neuss, Germany), respectively.
Plasma leptin levels were determined using a specific mouse ELISA kit
(Linco Research, Inc., St. Charles, MO).
Oxygen consumption measurements
Volume of O2 consumption in Zucker rats and ob/obmice was mea-
sured using an open-circuit indirect calorimetry system (MM-100 met-
abolic monitor system; CWE Inc., Ardmore, PA) as previously described
(3). Basal oxygen consumption was measured on 16-wk-old untreated
animals, within the 3 h after the start of the light cycle; no differences
were observed between animals within the same group. Then either a
single dose of tungstate, equivalent to 8 h consumed dose during chronic
ad libitum treatment (75 mg/kg body weight for rats and 60mg/kg body
weight formice), or vehicle (NaCl, 154mmol/liter), was administered by
gavage, and oxygen consumption was measured during the after 8 h. In
eWAT transplanted mice, measurements were performed for 23 h (from
1000 to 0900 h the next day) on 4-wk-treated or untreated transplanted
mice. All animals were previously housed overnight in the measurement
chamber to ensure acclimatization.
RNA isolation and quantitative RT-PCR analysis
BAT total RNA was purified by guanidine isothiocyanate-phenol
chloroform extraction (Invitrogen, Carlsbad, CA). For hypothalamus
total RNA purification RNA extraction minikit (Invitrogen) was used.
cDNA was synthesized using first-strand cDNA synthesis (Invitrogen)
from 1 g RNA following the manufacturer’s instructions. Synthesized
cDNA was subjected to quantitative RT-PCR (7900HT fast real time
TABLE 1. Quantitative RT-PCR primer pairs
Gene Forward (5–3) Reverse (5–3)
Ucp1 cgatgtccatgtaccacaaggaa tcgcagaaaagaagccacaa
CO-I cgccatcatattcgtaggagtaaa tctgagtagcgtcgtggtattcc
CO-IV ccgactggagcagcctttc tcggcgaagctctcgttaaa
Pgc1 tgatgacagtgaagatgaaagtgataaac ggcgacacatcgaacaatga
Acac gacttgcagaagaaatacgccata cttgtatcccttgtagggatcttca
Fasn tgctcccagctgcaggc gcccggtagctctgggtgta
Npy cgctctgcgacactacatcaa gggctggatctcttgccat
Agrp ggtgctagatccacagaaccg ccaagcaggactcgtgcag
Pomc agaggccactgaacatctttgtc gcagaggcaaacaagattgga
Cart ttctttcctcttgaagtgcttgtg gggaatatgggaaccgaaggt
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PCR system; Applied Biosystems, Foster City, CA), using in all cases
Power SYBR Green PCR master mix (Applied Biosystems), with the
exception of 18S rRNA, in which predesign Taqman probe and primers
(Applied Biosystems) were used. Cycle threshold values were calculated
usingAbIPrismSDSversion2.1 software (AppliedBiosystems), anddata
were normalized to values obtained for 18S rRNA. Results were ex-
pressed as arbitrary units (AU) normalized to values obtained for un-
treated mice from each experimental group. The primers used are de-
scribed in Table 1.
Statistical analysis
The data were statistically evaluated by a two-way mixed model
ANOVA, treatment fixed and time random. Subsequently we compared
all possible pairs of subgroups using the multiple comparisons Tukey’s
method with a 5% level of confidence. Differences between two means
were determined by Student’s test.
Results
Tungstate treatment decreased body weight gain and
adiposity in Zucker lean rats but not in fa/fa rats
Zucker ratswere treatedwith tungstate to determinewhether
tungstate was able to decrease body weight gain in this leptin
signaling-deficient model. As shown in Fig. 1A, oral administra-
tion of tungstate for 30 d reduced the bodyweight gain inZucker
lean rats by 27% compared with untreated rats, the difference
being significant (P 0.001). Moreover, a significant reduction
in leptin levels was observed in treated Zucker lean rats (4.23
0.36 ng/ml for untreated vs. 2.98 0.18 ng/ml for treated rats,
P  0.05). However, tungstate did not induce any significant
change inbodyweight gain and leptin levels inobeseZucker fa/fa
rats (Fig. 1B). As in diet-induced obese rats, tungstate treatment
improved the lipid profile of lean rats, decreasing circulating
levels of TG and NEFA compared with untreated rats (Table 2).
As expected, no improvement was observed in treated obese
Zucker fa/fa rats when compared with untreated rats.
To determine the mechanism of tungstate action involved in
the control of body weight, food intake measurements and in-
direct calorimetrywere performed.Tungstate treatment induced
a significant reduction in cumulative food intake (P 0.01) (Fig.
1C), bringing the average daily difference in food intake 5.90
0.32kcal.Tungstate also increasedoxygenconsumptionby16%
(P 0.05) (Fig. 1D) in Zucker lean rats. However, as shown in
Fig. 1, C and D, no changes in either cumulative food intake or
oxygen consumption were detected in tungstate-treated obese
Zucker fa/fa rats compared with untreated rats. Thus, tungstate
treatment did not change the energy balance in obese Zucker
fa/fa rats.
Interestingly, when Zucker animals were fed with high pal-
atable diet (cafeteria diet), body weight changes were similar to
the ones observed with standard diet. No changes in leptin re-
ceptor-deficient rats were observed, whereas a significant reduc-
tion in lean rats was detected when treated with tungstate (sup-
plemental Table 1, published as supplemental data on The
Endocrine Society’s Journals Online web site at http://endo.
endojournals.org). In contrast, nodifferences in food intakewere
observed among the groups as a consequence of tungstate treat-
ment (supplemental Fig. 1). This effect, as is discussed in Dis-
cussion, could be related to the hyperphagic stimulus induced by
high palatable diet.
FIG. 1. Oral tungstate treatment neither induces a negative energy balance nor
reduces body weight (BW) gain in leptin receptor-deficient Zucker rats.
Evaluation of 30 d tungstate treatment in 12-wk-old male obese Zucker fa/fa and
Zucker lean rats (n  9/group). Measurement of body weight gain evolution
during the treatment in lean (A; white squares, untreated; black squares, treated)
and fa/fa (B; white circles, untreated; black circles, treated) rats. C, Measurement
of cumulative food intake (FI; white squares, lean untreated; black squares, lean
treated; white circles, fa/fa untreated; black circles, fa/fa treated; n  9/group).
D, Oxygen consumption measurements in untreated obese Zucker lean and
Zucker fa/fa rats in response to a gavage administration of tungstate or vehicle
(white bars, vehicle; black bars, tungstate; n  6/group). Data are expressed as
mean  SEM. *, P  0.05 for untreated vs. treated animals.
TABLE 2. Oral tungstate treatment does not improve lipid profile in leptin-deficient animal models
Triglycerides (mg/ml) NEFA (nm)
UT T UT T
Zucker lean rats 83.52  7.60 65.35  3.77a 0.78  0.05 0.61  0.04a
Zucker fa/fa rats 375.04  27.39 375.35  47.58 1.90  0.11 1.94  0.16
Lean mice 132.20  5.34 105.41  8.91a 0.85  0.08 0.61  0.08a
ob/ob mice 156.45  7.93 148.25  7.57 1.38  0.13 1.30  0.12
Measurements of biochemical parameters at the end of 30 d tungstate treatment in Zucker lean and fa/fa rats and in lean and ob/ob mice (n  6/group). UT,
Untreated; T, treated. Data are expressed as mean  SEM.
a P  0.05 T vs. UT.
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Tungstate decreased body weight gain and adiposity in
lean but not ob/ob mice
To further analyze the effectiveness of tungstate treatment on
body weight regulation, we used an ob/obmouse model, which
lacks the expression of leptin. As expected, tungstate adminis-
tration promoted a significant reduction of body weight gain in
lean mice compared with age- and sex-matched untreated ones
(P 0.001) (Fig. 2A). This reduction in body weight cannot be
associatedwith a reduction in food intake, as is shown inpair-fed
experiments inwhichmice food intakewas restricted to the daily
amount of chow eaten by ad libitum-fed-treated animals (sup-
plemental Fig, 2). In these animals, tungstate treatment induce a
significant reduction of body weight gain (P  0.05) indepen-
dently of food intake because no differences were observed in
food intake during the experiment (10.60 0.06 kcal/d for un-
treated restricted food intake lean mice vs. 10.58  0.09 kcal/d
for tungstate-treated restricted food intake lean mice). As in
Zucker rats, tungstate did not change body weight gain in
ob/ob mice (Fig 2B). The lipid profile of lean mice was im-
proved by tungstate through a decrease in TG and NEFA
blood levels compared with untreated lean mice (Table 2).
Nevertheless, tungstate treatment did not change these pa-
rameters in ob/ob mice.
The study of energy balance in these animals also showed that
tungstate was effective only in lean mice, not in the ob/obmice.
On the one hand, tungstate treatment significantly reduced food
intake (P  0.05) (Fig. 2C), with an average daily food intake
difference of 2.40 0.12 kcal and simultaneously increased ox-
ygen consumption by a 20% (P  0.05) (Fig. 2D) in lean mice.
On the other hand, ob/ob mice showed no significant changes
due to tungstate treatment in either cumulative food intake or
oxygen consumption (Fig. 2, C and D). Overall, these results
indicate that leptin is necessary for tungstate to exert its effect on
body weight.
Leptin restoration in ob/ob mice allows tungstate to exert
its effect on body weight
Given the inability of tungstate to decrease body weight gain
in animals with leptin deficiency, we studied whether its effect
might be restored in ob/obmice with recovered leptin function.
Todo so,we established an adipose tissue transplantation protocol
to partially restore circulating leptin levels in ob/ob mice. In this
transplantation protocol, eWAT from lean mice was transplanted
sc into ob/obmice. From the secondweek after the transplant until
the end of the experiment, ob/ob txUT mice showed a significant
decrease in body weight gain compared with ob/ob txCN mice,
which were used as a control (4.99 0.92 for txUT vs. 5.38
0.31 g for txCNmice, P 0.001) (Fig. 3A).
FIG. 2. Oral tungstate treatment neither induces a negative energy balance nor
reduces body weight gain in leptin-deficient ob/ob mice. Evaluation of 30 d
tungstate treatment in 12-wk-old male ob/ob and lean mice (n  7/group).
Measurement of body weight gain evolution during the treatment in lean (A;
white squares, untreated; black squares, treated) and ob/ob (B; white circles,
untreated; black circles, treated) mice. C, Measurement of cumulative food
intake (FI; white squares, lean untreated; black squares, lean treated; white
circles, ob/ob untreated; black circles, ob/ob treated; n  9/group, n  7/group).
D, Oxygen consumption measurements in untreated ob/ob and lean mice in
response to a gavage administration of tungstate or vehicle (white bars, vehicle;
black bars, tungstate; n  6/group). Data are expressed as mean  SEM.
*, P  0.05 for untreated vs. treated mice.
FIG. 3. Restoration of leptin deficiency in ob/ob mice enables tungstate to exert
its antiobesity effects. Evaluation of 4 wk tungstate treatment in 12-wk-old ob/
ob mice transplanted with epididymal adipose tissue from ob/ob (ob/ob txCN,
n  6) or lean mice (ob/ob txUT or ob/ob txT, n  12/group). Measurement of
body weight gain evolution (A; black squares, untreated ob/ob txCN mice; white
circles, ob/ob txUT mice; gray triangles, ob/ob txT mice) and oxygen consumption
(B) was measured after 4 wk of transplantation, in overnight cage-acclimatized
mice and during 23 h (ob/ob txCN and ob/ob txUT, n  3/group; ob/ob txT, n 
5). C, Measurement of plasma leptin levels during the treatment. D, Evaluation of
tungstate treatment effects on transplanted adipose tissue removal from treated
transplanted ob/ob mice surgically excised mice (ob/ob ext) and ob/ob txT, n 
3/group. Measurement of body weight gain evolution at the end of the 2-wk
treatment period (black triangles, ob/ob txT mice; white squares, ob/ob ext mice).
Data are expressed as mean  SEM. **, P  0.01 and ***, P  0.001 for ob/ob
txUT or ob/ob txT vs. ob/ob txCN; ††, P  0.01 for ob/ob txUT vs. ob/ob txT.
LD values, Measurements under the limit detection of the method.
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Whereas circulating leptin levels were undetectable in ob/ob
txCN mice throughout the experiment, in ob/ob txUT mice, a
slight increase in leptin levels was observed a week after trans-
plant, which become significant after 2 wk and reached stable
levels afterward (Fig. 3B). These results indicate that this trans-
plant procedure partially increases leptin blood levels and also
restores the leptin functional system, leading to a decrease in
ob/ob mice body weight. Moreover, a significant reduction in
cumulative food intake (586 21 kcal per 4 wk for txCNmice
vs. 373 15 kcal per 4 wk for txUT; P 0.001) and an increase
in oxygen consumption (Fig. 3C) were observed in ob/ob txUT
mice compared with ob/ob txCN mice, leading to a change in
energy homeostasis which is in agreement with the reduction in
body weight gain detected.
When these transplantedanimalswere treatedwith tungstate,
the reduction of body weight accelerated. The difference was
already significant after 2 wk of treatment, and the end of the
experiment (4wk),ob/ob txTmicehad lost nearly twice the body
FIG. 4. Tungstate treatment induces BAT gene expression profile changes in
lean and ob/ob transplanted mice but not ob/ob mice. Measurement of Ucp1,
CO-I (mitochondrial DNA encoded), CO-IV (nuclear DNA encoded), Pgc1,
ACC (acetyl-Co-A carboxylase), and Fasn mRNA expression in BAT from lean
(A), ob/ob (B), and transplanted ob/ob (C) mice [ob/ob tx; white bars,
untreated (UT) mice; black bars, tungstate treated (T) mice; n  4 –5/group].
In the interests of clarity, gene expression levels were expressed as arbitrary
units normalized to values obtained for untreated mice of each experimental
group. Data are expressed as mean  SEM. *, P  0.05 and **, P  0.01 for
untreated vs. treated animals in each experimental group.
FIG. 5. Tungstate treatment induces changes in the hypothalamic neuropeptide
gene expression profile in lean mice but not ob/ob mice. Measurement of
hypothalamic neuropeptide mRNA expression in lean (A), ob/ob (B), and
transplanted ob/ob (C) mice [white bars, untreated (UT) mice; black bars,
tungstate treated (T) mice; n  4–6/group]. Data are expressed as mean  SEM.
*, P  0.05, for untreated vs. treated animals.
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weight lost by untreated animals (ob/ob txUT) (P 0.001) (Fig.
3A). Tungstate administration did not induce any change in cir-
culating leptin levels in the transplantedmice, suggesting that the
body weight decrease induced by tungstate was not due to an
increase in leptin (Fig. 3C). In this model of leptin deficiency
restoration, tungstate also reduced accumulated food intake
(373 15 kcal per 4 wk for txUT vs. 319 10 kcal per 4 wk for
txT mice; P  0.05), with a daily average difference of 1.93 
0.06 kcal. Furthermore, as shown in Fig. 3B, tungstate increased
oxygen consumption by 10% compared with untreated trans-
planted mice (ob/ob txUT) (P  0.01).
After 4 wk of treatment, transplanted fat depots were surgi-
cally excised in some of the ob/ob txT mice; tungstate adminis-
tration was then prolonged for 14 dmore. The excision of trans-
planted eWAT led to a rapid disappearance of circulating leptin
(data not shown) and an increase in the bodyweight gain in these
animals compared with the treated animals in which the trans-
plant was not removed (1.97  0.35 g for fat depots in excised
mice vs. 3.63  0.80 for txT mice; P  0.001), showing that
with the excision of fat depots the effectiveness of tungstate dis-
appears (Fig. 3D). Similar results were found in an additional
group of mice in which fat depots were excised and treatment
was then withdrawn. In these mice, leptin disappeared com-
pletely, and body weight gain reached similar values (2.57 
0.62 g) as in the excised mice treated with tungstate. Interest-
ingly, when treatment was withdrawn in transplanted mice, a
slow-down in body weight gain reduction was induced com-
pared with transplanted mice in which treatment continued
throughout the experiment (1.13  0.52 g; P  0.01 vs. ob/ob
txTmice). This reinforces the results that indicate that tungstate
acts on body weight in intact leptin system models.
To finally confirm the key role of leptin in the effects of tung-
state on body weight, a short-term treatment of recombinant
leptin was performed. After 5 d of leptin administration, a sig-
nificant reduction in body weight gain was observed in compar-
isonwithuntreatedob/obmice (5.340.47g for leptin treated
ob/obmice vs.1.260.19 g for leptin untreatedob/obmice,P
0.001). A higher decrease in body weight gain was detected in
those animals receiving oral tungstate at the same time as ip
leptin treatment (6.52  0.18 g for leptin- and tungstate-
treated ob/ob mice, P  0.05). Despite the differences in body
weight gain in these tungstate-treated animals, no differences
were detected in blood leptin levels between the two groups
(2.13 0.05 ng/ml for leptin-treated ob/obmice vs. 2.10 0.13
ng/ml for leptin and tungstate treated ob/ob mice).
Tungstate treatment induced changes in the expression
levels of genes involved in energy expenditure in BAT
of lean and ob/ob transplanted mice but not in
ob/ob mice
Previous studies have determined an increase in BAT ther-
mogenic-related genes and proteins (4, 5) in diet-induced obese
rats. To assess whether in our models BAT was also responsible
for the increase in whole-body energy expenditure in tungstate-
treated animals, we studied the expression pattern of several
genes involved in the thermogenic process. As expected, uncou-
pling protein (UCP)-1 expressionwas decreased in ob/obmice (a
2.7-fold reduction). Furthermore, leptin restoration in ob/ob
mice due to adipose tissue transplantation restored UCP1 ex-
pression (1.000.29AUfor leanmice; 0.370.09AUforob/ob
mice and1.270.15AU forob/ob txUTmice). As shown in Fig.
4, tungstate administration increased UCP1 expression 3-fold in
both lean and transplanted ob/obmice (P 0.01 and P 0.05,
respectively) compared with untreated mice, whereas in ob/ob
mice no significant treatment-related differences were observed.
Furthermore, the analysis of peroxisomal proliferator-activated
receptor- coactivator (PGC)-1 expression, a gene involved in
mitochondrial biogenesis, and cytochrome oxidase subunits 1
(CO-I) and 4 (CO-IV), belonging to the oxidative phosphoryla-
tion system, showed a similar expression pattern to UCP1, i.e. a
significant increase in lean and ob/ob txTmice due to tungstate
treatment (P 0.05 or P 0.01), and no changes in ob/obmice.
The expression levels of genes involved in lipid synthesis, such as
acetyl-CoA carboxylase and fatty acid synthase (FAS), was un-
changed by tungstate administration in all experimental models.
This finding suggests an adaptation of BAT to generate a mito-
chondrial proton gradient that can be used by UCP1 to increase
thermogenesis and the lack of any compensatory effects on the
opposite process, lipogenesis.
Tungstate administration modifies hypothalamic
neuropeptide gene expression profile in lean mice but
not ob/ob mice
To assess whether tungstate affects the gene expression of
hypothalamic neuropeptides involved in energy homeostasis,
which are classically regulated by leptin, we analyzed the ex-
pression of NPY, AGRP, POMC, and CART in the isolated hy-
pothalamus in treated and untreated lean, ob/ob, and trans-
planted ob/obmice. In leanmice, tungstate induced a significant
decrease of NPY (P  0.05) and AGRP (P  0.05), and an
increase in CART (P  0.05) gene expression (Fig. 5A), but no
changeswere observed in POMCgene expression.Moreover, no
differences in these genes were observed between ob/ob treated
and untreated animals (Fig. 5B). In contrast, when leptin defi-
ciency in ob/obmice was restored through adipose tissue trans-
plantation, neuropeptide expression changes due to tungstate
administration were similar to the ones observed in treated lean
mice (Fig. 5C). These results suggest that the effects of tung-
state on body weight may be mediated centrally, via action on
some of the neuropeptides involved in the regulation of energy
homeostasis.
Discussion
The results presented here improve our understanding of the
molecular mechanisms by which tungstate exerts its antiobesity
effects. In our previous studies (3), we reported that sodium
tungstate was able to reduce body weight gain and adiposity in
diet-induced obese rats, without modifying food intake or intes-
tinal lipid absorption. The main mechanism by which the treat-
ment reduces body weight gain is through an increase in energy
expenditure. Taking into account the key role that leptin plays in
the regulation of energy expenditure, we decided to investigate
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whether this adipokinewas important for tungstate’s antiobesity
activity.Wedemonstrate clearly that the leptin system is essential
for tungstate action because when either leptin or its receptor is
absent, tungstate is ineffective.Moreover,when leptin is restored
in the ob/ob model either by injection or transplant, tungstate
effectiveness returns. Therefore, the antiobesity activity of tung-
state depends entirely on a functional leptin system.
The data also show that adipose tissue transplantation is a
valid approach for restoring leptin deficiency in ob/obmice. Af-
ter the transplant, a significant decrease in body weight is ob-
served, simultaneous to the appearance of detectable circulating
leptin levels. However, our adipose tissue transplantation pro-
tocol could not completely restore leptin levels in comparison
with lean mice, reaching only a third of the lean mouse levels.
This is probably due to the fact thatwe transplanted only 500mg
of eWAT, which is approximately 10% of the total fat in lean
mice. Although eWAT is a depot with a high rate of leptin pro-
duction, it is unable to attain the leptin levels present in leanmice.
Nevertheless, the presence of circulating leptin levels, the reduc-
tion of body weight and food intake as well as the increase in
energy expenditure reported here show the viability of trans-
plantation. Furthermore, the increase observed in the vascular
regeneration of the transplanted tissue (data not shown) prob-
ably ensures a physiological leptin secretion in response to other
circulating factors such as NEFA or insulin (20, 21). Finally, we
cannot rule out a central contribution to the regulation of leptin
secretion in the transplanted depots, although Wang et al. (22)
showed that no regeneration of sympathetic enervation was ob-
served after 4 wk of fat transplantation.
In Zucker fa/fa rats, which are leptin receptor deficient, tung-
state was unable to decrease body weight gain or food intake or
increase energy expenditure. We conclude that tungstate needs
an intact leptin signaling system to exert its effects on energy
homeostasis. Furthermore, the fact that similar results were ob-
tained in treated ob/ob mice supports the hypothesis that tung-
state needs the endogenous hormone to act on body weight, and
suggests that tungstate does not act as an agonist of the leptin
receptor, but rather as a leptin enhancer. In both models, tung-
state does not modify TG andNEFA levels. Therefore, tungstate
is only able to improve the lipid profile when the treated animals
lose body weight, suggesting that this improvement is secondary
to the body weight reduction.
The importance of a functional leptin system is finally con-
firmed by the restitution of the tungstate effect on body weight,
food intake, and energy expenditure observed in the eWAT
transplantedob/obmicewith apartially restored leptin function.
Interestingly, in the treated transplanted mice, no increase in
leptin levels was observed. This result suggests that functional
leptin system is essential for the antiobesity action of sodium
tungstate because with the same levels of the hormone, the
treated transplanted mice had a higher decrease in body weight.
To rule out the possible contribution to tungstate’s antiobesity
activity of other adipokines secreted by the transplanted depots,
we performed a short-term treatment with recombinant leptin.
As expected, leptin administration reduced the body weight of
ob/obmice, and, as in the case of the transplantedmice, tungstate
treatment further enhanced this decrease.We therefore conclude
that leptin is the main adipokine involved in tungstate’s mech-
anism of action.
The oxygen consumption experiments performed in all our
animal models suggest that the energy expenditure increase as-
sociated with tungstate administration is mediated by leptin.
BAT is the most important thermogenic tissue in rodents (23).
UCP1, widely expressed in BAT, plays a key role in adaptive
thermogenesis by uncoupling ATP production from the oxida-
tive phosphorylation system, a process that has long been rec-
ognized as a protective mechanism against the development of
obesity (24). To evaluate the possible adaptation of BAT in the
tungstate increase inwhole-body energy expenditure,we studied
the expression pattern of several genes involved in the thermo-
genic process. Our results show clearly that tungstate increases
UCP1, PGC1, CO-I, and CO-IV gene expression only in ani-
mals with a functional leptin system. These results are in agree-
mentwithprevious results observed indiet-inducedobese rats (4,
5). This increase correlates perfectly with the rise in oxygen con-
sumption observed in the same experimental groups. In contrast,
the expression levels of genes involved in lipid synthesis (acetyl-
CoA carboxylase and FAS) remain unchanged in all tungstate-
treated animals. Taken together, these data indicate that tungstate
promotesanadaptationofBATtogenerateamitochondrialproton
gradient that can be used by UCP1 to increase thermogenesis and
energy expenditure and exert a positive effect on weight loss and
avoid the use of this mitochondrial proton gradient in the lipid
synthesis process.
In earlier experiments performed with diet-induced obese
rats, tungstate administration had no effect on food intake, and
we postulated that the decrease in body weight gain was the sole
cause of the increase in energy expenditure (3). However, the
results presented in this paper show that tungstate treatment
reduced food intake in animals with a functional leptin system
and, in combinationwith the lack of tungstate aversion in drink-
ing water (supplemental Fig. 2) determined by two bottle pref-
erence test performed in Wistar and C57BL/6 mice, suggests an
anorectic effect of tungstate when no hyperphagic stimulus, due
to hypercaloric diet, is present. Previous studies reported a de-
crease in food intake in other animal models (5). These differ-
ences may be due to the hyperphagia induced in diets with high
palatability (25), which is the case of the cafeteria diet used in
diet-induced obesity experiments. Diets of this type could induce
powerful orexigenic signals (26) that may mask the anorectic
effects of tungstate. Although the hyperphagic stimulus due to
palatability usually subsides within a few days and food intake
stabilizes afterward, this is not the case of the cafeteria diet
model, which, as we and others have reported, does not normal-
izewithin 30 d (27).However, because no data for longer studies
are available, we cannot conclude that the disappearance of an-
orectic effects of tungstate is due exclusively to diet palatability.
Food intake regulation involves the activation of several neuro-
nal centers, such as reward, satiety, or hunger perception (28,
29), and further analysis is needed to determine whether tung-
state modulates any of them. Another possible explanation for
the differences observed in food intake is the rapid leptin resis-
tance induced by high-fat diets (30). In this situation, it may be
that tungstate cannot enhance leptin’s suppressive effect on food
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intake. In any case, further studies are underway todetermine the
causes of the differences in anorectic behavior recorded in the
two dietetic groups.
Leptin regulates food intakeandenergy expenditurebyacting
on several brain centers, the arcuate nuclei being the main one
(14–18). It is well established that leptin only regulates UCP1
mRNA expression by acting centrally through the sympathetic
innervation and not directly on BAT (19, 31, 32). Interestingly,
when tungstate is administered intracerebroventricularly, it in-
duces a decrease in food intake (Claret, M., personal communi-
cation).Moreover, previous studies on the toxicology and phar-
macology of sodium tungstate showed that when administered
orally, tungstate could be detected in the brain by using inducted
coupled plasma techniques (Barbera, A., personal communica-
tion). Therefore, it can be reasonably assumed that tungstate can
cross the blood-brain barrier and exert its action on the regula-
tion of energy homeostasis neuropeptides.
Finally, we wanted to assess whether tungstate effects on en-
ergy homeostasis involved a central mechanism, through the en-
hancement of leptin action. To do so, we studied the expression
levels of the key hypothalamic neuropeptides involved in the
energy balance, which are regulated by leptin (15–18, 33). The
results presentedhere showa leptin-mediated regulationofNPY,
AGRP, and CART, but not POMC gene expression, in response
to tungstate treatment. These results suggest a hypothalamus-
mediated effect of tungstate on leptin-regulated genes, resulting
in the modulation of food intake and energy expenditure as
mechanisms of bodyweight regulation.However, no differences
were observed in POMC gene expression due to tungstate treat-
ment. This lack of effect of tungstate on POMC has also been
observed in other models with altered leptin signaling pathway:
suppressor of cytokine signaling haploinsufficient mice (34),
small heterodimer partner-2 (35), and Src homology-2B (36)-
deficient mice. All these proteins are involved in leptin receptor
downstream signaling regulation, suggesting that leptin-me-
diated energy homeostasis regulation could be exerted by
POMC alternative neural signals. Obviously, due to the wide
distribution of leptin receptor expression in a variety of tissues
(37), we cannot rule out the possibility that tungstate may act
either peripherally or in other neuronal centers to exert its
effects on energy expenditure. We are currently performing a
range of experiments to assess these possibilities. The prelim-
inary results indicate that tungstate does not affect the dopa-
minergic stimulus on the accumbens nuclei, suggesting that it
does not affect this reward center. However, further studies in
this and other areas of the brain are necessary to determine
their contribution on tungstate actions on food intake and
energy expenditure.
In summary, the body weight reduction effect of tungstate is
dependent on a functional leptin system. Tungstate acts by re-
ducing food intake and increasing BAT-mediated thermogenesis
(mechanisms that promote the reduction of bodyweight gain) in
a leptin-dependent manner. Furthermore tungstate action is me-
diated, at least in part, by an increase in the expression of neu-
ropeptides related to energy homeostasis regulation.
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